ArticleThe Journal of membrane biology2026
Structural Basis of SERCA Inhibition by Derivatives of di-tert-butylhydroquinone Revealed by X-ray Crystallography.
Article in The Journal of membrane biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The small molecule di-tert-butylhydroquinone (BHQ) is a potent inhibitor of the sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA). It inhibits the enzyme by stabilizing it in its E2 conformation and thereby preventing the transition to the E1 state. To define the structural determinants underlying BHQ inhibition, we examined ten BHQ derivatives with systematic modifications of polar and hydrophobic substituents of different shapes and sizes. Inhibitory potencies were determined in ATPase activity assays, and crystal structures of SERCA1a in complex with eight of the ten derivatives were obtained at resolutions of 2.6 Å or better, aided by co-crystallization of thapsigargin to stabilize the E2 state. The structures revealed that the compounds bind in a pocket formed by transmembrane helices M1-M4, in which the ligand is stabilized by CH-π interactions between the central benzene ring and Leu61 and Pro312, by hydrogen bonds - preferentially involving Asp59 - and by extensive van der Waals contacts mediated by two butyl substituents. Analysis of the SERCA/inhibitor poses showed that while at least one hydrogen bond is required for binding, inhibitory potency correlates strongly with the number and quality of van der Waals contacts mediated by appropriately positioned alkyl groups. Compounds lacking alkyl substituents or containing oversized or mispositioned groups displayed markedly reduced potencies. Although no derivative exceeded BHQ in inhibitory activity, structural analysis suggests that repositioning hydroxy groups on the benzene ring or modifying alkyl substituents may further optimize binding affinity and thus inhibitory potency. Together, these results define the key molecular features of SERCA inhibition by BHQ analogs and suggest strategies for further optimization of this inhibitor class.
Indexed as
Identifiers
42371092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.